20240825-太平洋-三星医疗-601567.SH-三星医疗2024年半年报点评_配用电海外市场不断突破_医疗服务业持续连锁布局_5页_644kb

总结：三星医疗2024年半年报业绩点评

这份报告深入分析了三星医疗（601567）2024年上半年的经营表现。公司2024年半年度报告显示收入6997亿元，同比增长2611%，归母净利润达到1150亿元，同比增长3223%，远超市场预期。具体表现为：

• 智能配电业务增长显著：报告期内智能配用电业务收入达5380亿元，同比增长2628%。海外在手订单总额6220亿元，同比增幅404%。
• 医疗服务稳健扩张：医疗服务业务收入同比增长2653%，其中康复医疗业务增幅显著。截至6月底，医院数量达34家，康复医院28家，布局持续扩张。
• 盈利能力持续增强：毛利率从去年的28.88%升至本年的34.61%，其中第二季度达到37.21%。尽管销售和研发费用上升，但公司的净利润率提升显著，ROE（净资产收益率）达99.7%，未来维持较高的盈利水平。

展望未来，太平洋证券维持“买入”评级，预测公司2024至2026年营收复合增长率为27%-22%，净利润增长稳健。股价对应PE分别为19、16、13倍，研究建议提升关注。

English Summary: Samsung Medivac 2024 H1 Report Commentary

This report analyzes Samsung Medivac's (601567) performance in the first half of 2024. The company achieved revenue of RMB 69.97 billion with a year-on-year growth of 2,611% and net profit attributable to shareholders of RMB 11.5 billion, up 322%. Key highlights:

• Significant Growth in Smart Power Distribution
  The smart distribution business reported revenue of RMB 53.8 billion, growing +262.8%. Orders in hand, especially in Europe and Latin America, saw substantial increases.

• Solid Expansion in Healthcare Services
  Healthcare revenue reached RMB 16.1 billion (+265.3%), led by rehabilitation hospital services. As of the end of June, the company has 34 hospitals, 28 of which specialize in rehabilitation.

• Improved Profit Margins
  Profit margin jumped to 34.6% in the first half, with a further rise to 37.2% in Q2. Higher costs for sales and R&D were offset by improved operational efficiency.

Looking forward, Samsung Medivac is maintained at a BUY recommendation with an upside valuation from 19x to 13x PE over the next three years. The company's dual drivers in power distribution and healthcare position it for continued growth.